Clinical trial
Multiple Dose Study of Aducanumab (BIIB037) (Recombinant, Fully Human Anti-Aβ…
NCT01677572 · Biogen, Industry · Terminated
Key facts
| NCT number | NCT01677572 |
|---|---|
| Title | Multiple Dose Study of Aducanumab (BIIB037) (Recombinant, Fully Human Anti-Aβ IgG1 mAb) in Participants With Prodromal or Mild Alzheimer's Disease |
| Official title | A Randomized, Double-Blinded, Placebo-Controlled Multiple Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB037 in Subjects With Prodromal or Mild Alzheimer's Disease |
| Acronym | PRIME |
| Lead sponsor | Biogen, Industry |
| Status | Terminated |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Alzheimer's Disease |
| Intervention type | Drug |
| Interventions | Aducanumab (recombinant, fully human anti-Aβ IgG1 mAb), Placebo |
| Enrollment | 197 |
| Start date | Oct 5, 2012 |
| Primary completion | Jul 31, 2019 |
| Completion | Jul 31, 2019 |
| First posted | Sep 3, 2012 |
| Last update posted | Aug 3, 2020 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- 1–9 Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: